OBJECTIVES: Microbial adhesion and biofilms have important implications for human health and disease. Candida albicans is an opportunistic pathogen which forms drug-resistant biofilms that contribute to the recalcitrance of disease. We have developed a high-throughput screen for potentiators of clotrimazole, a common therapy for Candida infections, including vaginitis and thrush. The screen was performed against C. albicans biofilms grown in microtitre plates in order to target the most resilient forms of the pathogen. METHODS: Biofilm growth, in individual wells of 384-well plates, was measured using the metabolic indicator alamarBlue® and found to be very consistent and reproducible. This assay was used to test the effect of more than 120 000 small molecule compounds from the NIH Molecular Libraries Small Molecule Repository, and compounds that enhanced the activity of clotrimazole or acted on the biofilms alone were identified as hits. RESULTS: Nineteen compounds (0.016% hit rate) were identified and found to cause more than 30% metabolic inhibition of biofilms compared with clotrimazole alone, which had a modest effect on biofilm viability at the concentration tested. Hits were confirmed for activity against biofilms with dose-response measurements. Several compounds had increased activity in combination with clotrimazole, including a 1,3-benzothiazole scaffold that exhibited a >100-fold improvement against biofilms of three separate C. albicans isolates. Cytotoxicity experiments using human fibroblasts confirmed the presence of lead molecules with favourable antifungal activity relative to cytotoxicity. CONCLUSIONS: We have validated a novel approach to identify antifungal potentiators and completed a high-throughput screen to identify small molecules with activity against C. albicans biofilms. These small molecules may specifically target the biofilm and make currently available antifungals more effective.
OBJECTIVES: Microbial adhesion and biofilms have important implications for human health and disease. Candida albicans is an opportunistic pathogen which forms drug-resistant biofilms that contribute to the recalcitrance of disease. We have developed a high-throughput screen for potentiators of clotrimazole, a common therapy for Candida infections, including vaginitis and thrush. The screen was performed against C. albicans biofilms grown in microtitre plates in order to target the most resilient forms of the pathogen. METHODS: Biofilm growth, in individual wells of 384-well plates, was measured using the metabolic indicator alamarBlue® and found to be very consistent and reproducible. This assay was used to test the effect of more than 120 000 small molecule compounds from the NIH Molecular Libraries Small Molecule Repository, and compounds that enhanced the activity of clotrimazole or acted on the biofilms alone were identified as hits. RESULTS: Nineteen compounds (0.016% hit rate) were identified and found to cause more than 30% metabolic inhibition of biofilms compared with clotrimazole alone, which had a modest effect on biofilm viability at the concentration tested. Hits were confirmed for activity against biofilms with dose-response measurements. Several compounds had increased activity in combination with clotrimazole, including a 1,3-benzothiazole scaffold that exhibited a >100-fold improvement against biofilms of three separate C. albicans isolates. Cytotoxicity experiments using human fibroblasts confirmed the presence of lead molecules with favourable antifungal activity relative to cytotoxicity. CONCLUSIONS: We have validated a novel approach to identify antifungal potentiators and completed a high-throughput screen to identify small molecules with activity against C. albicans biofilms. These small molecules may specifically target the biofilm and make currently available antifungals more effective.
Authors: Gordon Ramage; Stefano Bachmann; Thomas F Patterson; Brian L Wickes; José L López-Ribot Journal: J Antimicrob Chemother Date: 2002-06 Impact factor: 5.790
Authors: Kaat De Cremer; Ellen Lanckacker; Tanne L Cools; Marijke Bax; Katrijn De Brucker; Paul Cos; Bruno P A Cammue; Karin Thevissen Journal: Antimicrob Agents Chemother Date: 2014-11-03 Impact factor: 5.191
Authors: Aaron D Mood; Ilandari Dewage Udara Anulal Premachandra; Stanley Hiew; Fuqiang Wang; Kevin A Scott; Nathan J Oldenhuis; Haoping Liu; David L Van Vranken Journal: ACS Med Chem Lett Date: 2017-01-11 Impact factor: 4.345
Authors: Christopher G Pierce; Anand Srinivasan; Priya Uppuluri; Anand K Ramasubramanian; José L López-Ribot Journal: Curr Opin Pharmacol Date: 2013-09-04 Impact factor: 5.547
Authors: Ann R Holmes; Tony S Cardno; J Jacob Strouse; Irena Ivnitski-Steele; Mikhail V Keniya; Kurt Lackovic; Brian C Monk; Larry A Sklar; Richard D Cannon Journal: Future Med Chem Date: 2016-07-27 Impact factor: 3.808
Authors: Matthew B Lohse; Megha Gulati; Ashley Valle Arevalo; Adam Fishburn; Alexander D Johnson; Clarissa J Nobile Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191